Infection with stomach bacteria may increase risk of Alzheimer's disease
Helicobacter pylori enters the central nervous system
Infection with the stomach bacterium Helicobacter pylori could increase the risk of developing Alzheimer’s disease: In people over the age of 50, the risk following a symptomatic infection can be an average of 11 percent higher, and even more about ten years after the infection, at 24 percent greater risk. These are the findings of a study by Charité – Universitätsmedizin Berlin and McGill University (Canada), now published in the journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association. The researchers analyzed three decades’ worth of patient data.
As today’s populations age, dementia is set to become more common, tripling in prevalence in the next 40 years. With no cure in sight so far, researchers are trying to pinpoint the risk factors involved in dementia, in hopes of specifically targeting those factors.
Helicobacter pylori enters the central nervous system
Researchers have long suspected Helicobacter pylori, a common gut microbe, of being a potential risk factor. Nearly one-third of all people in Germany are infected with this type of bacteria. An infection can be asymptomatic, but the bacteria can also cause inflammation of the stomach lining or even stomach cancer. Numerous lab studies have also found a link between H. pylori infection and the central nervous system. “We know that the bacterium can reach the brain via various routes, potentially causing inflammation, damage, and the destruction of neurons there,” explains Prof. Antonios Douros, a pharmacoepidemiologist at Charité and the first author of the study. When the stomach has been damaged by these microbes, it is also no longer able to absorb Vitamin B12 or iron effectively, which also increases the risk of dementia.
However, many of the studies performed to date on the association between H. pylori infection and Alzheimer’s disease suffered from methodological limitations – for example because the number of people studied was simply too low. One outcome of this was that before now, it was also not possible to say just how strong a link there is between this type of bacterial infection and Alzheimer’s disease.
Representative study of over four million people
Douros, Prof. Paul Brassard of McGill University in Montreal, and their colleagues have now compensated for those limitations. Not only did their study have a very large sample size, at over four million people, but it also considered the time interval between infection and a possible increase in the risk of Alzheimer’s disease. The researchers used data gleaned from electronic patient records in the UK to quantify the link between H. pylori and Alzheimer’s disease over the course of a person’s lifetime.
“Our study shows that symptomatic infections with H. pylori after the age of 50 can be associated with an eleven percent increase in the risk of Alzheimer’s disease. The risk increase peaks at 24 percent about a decade after the initial infection,” Douros says, summarizing the team’s findings. But that doesn’t mean everyone who has experienced a symptomatic infection will necessarily go on to develop Alzheimer’s disease. The calculations show an increase in the relative risk compared to people who did not experience a symptomatic H. pylori infection after the age of 50.
Are H. pylori infections a modifiable risk factor?
“To us, this finding reinforces the assumption that an H. pylori infection could be a modifiable risk factor for Alzheimer’s disease,” Douros concludes. However, the researchers caution that whether efforts to eradicate this gut microbe might actually affect the development of Alzheimer’s disease, and if so to what extent, would need to be tested in large-scale randomized studies first.
Original publication
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Messe München International takes over one of India's leading trade fairs for laboratory technology
Melatonin boost a key to fighting breast cancer
Alentis Therapeutics Raises USD 67 Million in Series B Financing - Funding to Advance Pipeline of Anti-fibrotic Molecules into the Clinic
Key advance toward production of important biofuel - MOF can efficiently separate biobutanol from the fermentation broth
Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis - Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF
Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
Fruit peels for cleaning wastewater - Wastewater cleaned thanks to a new adsorbent material made from fruit peels
Thermo Scientific Orbitrap Exploris | Orbitrap mass spectrometers | Thermo Fisher Scientific
Siegfried signs comprehensive cooperation agreement with Arena Pharmaceuticals
SEEK announces clinical proof of efficacy in HIV vaccine Phase Ib/II human trial - 90% reduction in HIV viral load demonstrated compared with normal disease progression
World's biggest study on cell phones and brain cancer inconclusive
